Kronos Bio, Inc. (KRON)

NASDAQ: KRON · IEX Real-Time Price · USD
1.64
-0.03 (-1.80%)
Dec 7, 2022 11:54 AM EST - Market open
-1.8%
Market Cap 95.02M
Revenue (ttm) n/a
Net Income (ttm) -163.76M
Shares Out 56.32M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,708
Open 1.67
Previous Close 1.67
Day's Range 1.61 - 1.72
52-Week Range 1.61 - 15.8
Beta 1.10
Analysts Buy
Price Target 11.63 (+609.1%)
Earnings Date Nov 8, 2022

About KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of entospletinib in combination with induction chemotherapy ... [Read more]

Industry Biotechnology
IPO Date Oct 9, 2020
Employees 101
Stock Exchange NASDAQ
Ticker Symbol KRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for KRON stock is "Buy." The 12-month stock price forecast is 11.63, which is an increase of 609.15% from the latest price.

Price Target
$11.63
(609.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kronos Bio Announces Participation in Upcoming Investor Conferences

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that...

2 weeks ago - GlobeNewsWire

Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks

Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...

2 weeks ago - Zacks Investment Research

Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742

4 weeks ago - GlobeNewsWire

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

Company to discontinue Phase 3 entospletinib trial for strategic reasons

4 weeks ago - GlobeNewsWire

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediat...

Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Ph...

1 month ago - GlobeNewsWire

Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious di...

3 months ago - GlobeNewsWire

Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib...

SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient ha...

3 months ago - GlobeNewsWire

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational ...

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is curre...

3 months ago - PRNewsWire

Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 311.9% upside potential for Kronos Bio, Inc. (KRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

3 months ago - Zacks Investment Research

Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

Company continuing to enroll patients in both Phase 3 registrational AGILITY trial of entospletinib and Phase 1/2 KB-0742 trial; both programs remain on track

4 months ago - GlobeNewsWire

7 Nasdaq Stocks to Buy on the Dip

If you want to maximize your return potential and can handle some heat, here are compelling Nasdaq stocks to buy on the dip. The post 7 Nasdaq Stocks to Buy on the Dip appeared first on InvestorPlace.

Other symbols: CRCTGPLYFTNFLXPYPLVERI
4 months ago - InvestorPlace

Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know

Kronos Bio, Inc. (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Dat...

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemia Posters include preclinical data o...

5 months ago - GlobeNewsWire

Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious dise...

6 months ago - GlobeNewsWire

Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations...

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML)

6 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and  additional ...

7 months ago - GlobeNewsWire

Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Effic...

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including  sarcoma and chordoma

7 months ago - GlobeNewsWire

Kronos Bio's Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at Americ...

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma Posters also feature data from precl...

8 months ago - GlobeNewsWire

Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious di...

9 months ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022

9 months ago - GlobeNewsWire

Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious dis...

10 months ago - GlobeNewsWire

Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Di...

Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for...

1 year ago - GlobeNewsWire

Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

Initial data demonstrate long plasma half-life and dose-dependent target inhibition

1 year ago - GlobeNewsWire

Kronos Bio Appoints Roshawn Blunt to Board of Directors

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the ...

1 year ago - GlobeNewsWire

Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results

Company today announces progression of two discovery programs within its pipeline

1 year ago - GlobeNewsWire